This study is currently not recruiting participants.

A Phase 3 Multicenter Investigator-blind Randomized Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h and Vancomycin Oral Liquid or Capsules Taken q6h for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea

  • STATUS
    Not Recruiting
Updated on 19 February 2024

Summary

This is a multi-center, open label study designed to evaluate the safety and tolerability of Fidaxomicin oral suspension or tablets in pediatric subjects, ages 6 months to 18 years of age with Clostridium difficile-associated diarrhea (CDAD), following the administration of doses given every 12 hours for 10 consecutive days.

Description

This is a multi-center, open label study designed to evaluate the safety and tolerability of Fidaxomicin oral suspension or tablets in pediatric subjects, ages 6 months to 18 years of age with Clostridium difficile-associated diarrhea (CDAD), following the administration of doses given every 12 hours for 10 consecutive days.

Details
Condition Clostridium difficile-associated Diarrhea
Age 100years or below
Clinical Study IdentifierTX4380
Last Modified on19 February 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.